Osong Public Health and Research Perspectives

Original Articles

The Moderating Role of Social Activity on Age Norms and Subjective Health Status of Older Adults: A Two-Stage Cluster Korea National Survey: Myungsuk Choi, Minsung Sohn, Sangsik Moon, Mankyu Choi; Osong Public Health Res Perspect. 2019;10(3):145-151. Published online June 30, 2019; DOI: https://doi.org/10.24171/j.phrp.2019.10.3.05

5,390 View
122 Download
1 Crossref

Objectives

This study aimed to examine how social activity (SA) moderates the relationship between age norms (AN) and subjective health status (SHS) among older adults in Korea. Based on the theories of age-integrated structure and active aging, the proposed hypotheses were that SHS has a positive association with attitudes towards AN, and with the interactions between different types of AN and SA.

Methods

Cross-sectional data from a Korean national survey of older adults were analyzed. Participants were older adults N = 10,451, of whom 10,280 were used in the study sample. Multivariate linear regression including interaction terms, was used to examine the associations among SHS, AN, and SA.

Results

The results of multivariate linear regression examining learning (ß = 0.066, p < 0.001), working (ß = 0.063, p < 0.001), and remarriage (ß = 0.036, p < 0.001) showed that those who perceived AN more positively, were more likely to have a high SHS. With interaction terms, those who had a positive attitude towards AN for learning and volunteering (ß = 0.025, p < 0.05), and remarriage and engaged in friendship groups (ß = 0.032, p < 0.05) were more likely to have a high SHS.

Conclusion

SA serves as a great moderator between AN and SHS.

Citations

Citations to this article as recorded by

Social engagement and subjective health among older adults in South Korea: Evidence from the Korean Longitudinal Study of Aging (2006–2018)
Bo Zhao, Ji Eon Kim, Jiyoung Moon, Eun Woo Nam
SSM - Population Health.2023; 21: 101341. CrossRef

Factors Related to Healthcare Service Quality in Long-term Care Hospitals in South Korea: A Mixed-methods Study: Minsung Sohn, Mankyu Choi; Osong Public Health Res Perspect. 2017;8(5):332-341. Published online October 31, 2017; DOI: https://doi.org/10.24171/j.phrp.2017.8.5.07

4,721 View
35 Download
2 Crossref

Abstract PDF

Objectives

The environment of long-term care hospitals (LTCHs) is critical to the management of the quality of their services and to patient safety, as highlighted by international studies. However, there is a lack of evidence on this topic in South Korea. This study aimed to examine the factors affecting healthcare quality in LTCHs and to explore the effectiveness of their quality management.

Methods

This study used a mixed methods approach with quantitative data collected in a national survey and qualitative data from semi-structured interviews with practice-based managers. The samples included 725 nationally representative LTCHs in South Korea for the quantitative analysis and 15 administrators for the in-depth interviews.

Results

A higher installation rate of patient-safety and hygiene-related facilities and staff with longer-tenures, especially nurses, were more likely to have better healthcare quality and education for both employees and patients.

Conclusion

The need for patient-safety- and hygiene-related facilities in LTCHs that serve older adults reflects their vulnerability to certain adverse events (e.g., infections). Consistent and skillful nursing care to improve the quality of LTCHs can be achieved by developing relevant educational programs for staff and patients, thereby strengthening the relationships between them.

Citations

Citations to this article as recorded by

Improving Preparedness for and Response to Coronavirus Disease 19 (COVID-19) in Long-Term Care Hospitals in Korea
Tark Kim
Infection & Chemotherapy.2020; 52(2): 133. CrossRef
Identifying Potentially Avoidable Emergency Department Visits of Long-Term Care Hospital Residents in Korea: A Multicenter Retrospective Cohort Study
Keon Kim, Dong Hoon Lee, Ho Young Yune, Jung Hee Wee, Duk Ho Kim, Eui Chung Kim, Jee Yong Lim, Seung Pil Choi
BioMed Research International.2019; 2019: 1. CrossRef

The Determinants of Research and Development Investment in the Pharmaceutical Industry: Focus on Financial Structures: Munjae Lee, Mankyu Choi; Osong Public Health Res Perspect. 2015;6(5):302-309. Published online October 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.10.013

3,192 View
18 Download
23 Crossref

Abstract PDF

Objectives
This study analyzes the influence of the financial structure of pharmaceutical companies on R&D investment to create a next-generation profit source or develop relatively cost-effective drugs to maximize enterprise value.
Methods
The period of the empirical analysis is from 2000 to 2012. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association (KLCA), and data related to stock price is extracted from KISVALUE-Ⅲ of NICE Information Service Co., Ltd. Stata 12.0 was used as the statistical package for panel analysis.
Results
The current ratio had a positive influence on R&D investment, the debt ratio had a negative influence on R&D investment, and return on investment and net sales growth rate did not have a significant influence on R&D investment.
Conclusion
It was found in this study that the higher liquidity ratio, the greater the R&D investment. The stability of pharmaceutical companies has a negative influence on R&D investment. This finding is consistent with the prediction that if a company faces a financial risk, it will be passive in R&D investment due to its financial difficulties.

Citations

Citations to this article as recorded by

Does Business Group Affiliation Enhance Firm-level Innovation? Evidence from Indian Automotive Components Industry
J. Vineesh Prakash, D. K. Nauriyal
The Indian Economic Journal.2024;[Epub] CrossRef
How Indian Pharma Industry Performed in the Last Decade? Impact of a Non-macroeconomic Variable and Financial Distress
Pooja Singh, Anindita Chakraborty
Jindal Journal of Business Research.2023; 12(2): 143. CrossRef
How structural changes are driving R&D activity in India’s pharmaceutical sector
Niloufer Sohrabji, Kristen Marquette
Journal of Pharmaceutical Health Services Research.2023; 14(3): 256. CrossRef
Patent and Marketing Exclusivities 101 for Drug Developers
Bryan Oronsky, Scott Caroen, Franck Brinkhaus, Tony Reid, Meaghan Stirn, Raj Kumar
Recent Patents on Biotechnology.2023; 17(3): 257. CrossRef
The driving process of technological innovation in construction: a firm-level CDM analysis
Zheng Gong, Nannan Wang
Construction Innovation .2022; 22(2): 222. CrossRef
Envisioning the challenges of the pharmaceutical sector in the Indian health-care industry: a scenario analysis
Giuseppe Festa, Ashutosh Kolte, Maria Rosaria Carli, Matteo Rossi
Journal of Business & Industrial Marketing.2022; 37(8): 1662. CrossRef
Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design
Yu-Fei Hua, Jin Lu, Bing Bai, Han-Qing Zhao
Frontiers in Public Health.2022;[Epub] CrossRef
Ambidexterity's influence on export strategy development—The case of the Indian pharmaceutical industry
Ashutosh Kolte, Giuseppe Festa, Matteo Rossi, Alkis Thrassou, Demetris Vrontis, Michael Christofi
Thunderbird International Business Review.2022; 64(5): 465. CrossRef
Local pharmaceutical research and development capacity in a developing country: a qualitative exploration of perspectives from key stakeholders in Ethiopia
Muluken Nigatu Selam, Samuel Abera, Helen Geremew, Eskinder Eshetu Ali
Journal of Pharmaceutical Policy and Practice.2022;[Epub] CrossRef
Optimization and Quest of HPMC loaded Stavudine Controlled Release Dosage Development by Central Composite Design utilizing Reduced Factorial Screening Technique
Jyothsna Gangolu, Sandyapakula Balaiah, Sisir Nandi, Harekrishna Roy
Brazilian Journal of Pharmaceutical Sciences.2022;[Epub] CrossRef
The contribution of intellectual capital to financial stability in Indian pharmaceutical companies
Giuseppe Festa, Matteo Rossi, Ashutosh Kolte, Luca Marinelli
Journal of Intellectual Capital.2021; 22(2): 337. CrossRef
Factors affecting profitability of pharmaceutical company: an Indonesian evidence
Harianto Lim, Rofikoh Rokhim
Journal of Economic Studies.2021; 48(5): 981. CrossRef
Impact of Monetary Policy Uncertainty on R&D Investment Smoothing Behavior of Pharmaceutical Manufacturing Enterprises: Empirical Research Based on a Threshold Regression Model
Jingyuan Yang, Ling Wang, Ziyuan Sun, Fangming Zhu, Yihui Guo, Yan Shen
International Journal of Environmental Research an.2021; 18(21): 11560. CrossRef
Drivers of ICT investments in bakery and sugar confectionery processed food sub-sector in India
Navyashree GR, Savita Bhat
Journal of Agribusiness in Developing and Emerging.2020; 10(2): 191. CrossRef
Gouvernance et intensité d’innovation dans les ETI innovantes
Léopold Djoutsa Wamba, Éric Braune, Frédéric Teulon
Management & Avenir.2020; N° 118(4): 111. CrossRef
MALİYET YAPIŞKANLIĞININ YENİDEN GÖZDEN GEÇİRİLMESİ: BORSA İSTANBUL İMALAT SANAYİ ÖRNEĞİ
Mehmet Emin KARABAYIR
Muhasebe ve Vergi Uygulamaları Dergisi.2019; 12(2): 317. CrossRef
Bioaugmentation effect of Aeromonas hydrophila and Pseudomonas putida on kinetics of activated sludge process in treating pharmaceutical industrial wastewater
Marija Vuković Domanovac, Monika Šabić Runjavec, Ernest Meštrović
Journal of Chemical Technology & Biotechnology.2019; 94(8): 2721. CrossRef
Replicating the R&D investments and financial structure relationship: evidence from Borsa İstanbul
Nasif Ozkan
Management Review Quarterly.2018; 68(4): 399. CrossRef
Firm level R&D intensity: evidence from Indian drugs and pharmaceutical industry
Shilpi Tyagi, D. K. Nauriyal, Rachita Gulati
Review of Managerial Science.2018; 12(1): 167. CrossRef
Impact of investment in intangible assets on corporate performance in India
Aparna Bhatia, Khushboo Aggarwal
International Journal of Law and Management.2018; 60(5): 1058. CrossRef
Relation of R&D expense to turnover and number of listed companies in all industrial fields
Jun-Hwan Park, Bangrae Lee, Yeong-Ho Moon, GyuSeok Kim, Lee-Nam Kwon
Journal of Open Innovation: Technology, Market, an.2018; 4(1): 1. CrossRef
Policy to encourage the development of antimicrobials
Ayman Chit, Paul Grootendorst
International Journal of Health Governance.2018; 23(2): 101. CrossRef
O IMPACTO DOS INVESTIMENTOS EM P&D NO DESEMPENHO DAS EMPRESAS: APLICAÇÕES NO USO DE REGRESSÃO QUANTÍLICA COM VARIÁVEIS INSTRUMENTAIS
Leonardo Andrade Rocha, Ahmad Saeed Khan, Patrícia Verônica Pinheiro Sales Lima, Maria Ester Soares Dal Poz, Carlos Alano Soares de Almeida
Revista de Economia Contemporânea.2018;[Epub] CrossRef

Analysis on Time-Lag Effect of Research and Development Investment in the Pharmaceutical Industry in Korea: Munjae Lee, Mankyu Choi; Osong Public Health Res Perspect. 2015;6(4):241-248. Published online August 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.07.001

3,283 View
16 Download
15 Crossref

Abstract PDF

Objectives
The aim of this study is to analyze the influence of the research and development (R&D) investment of pharmaceutical companies on enterprise value.
Methods
The period of the empirical analysis is from 2000 to 2012, considering the period after the influence of the financial crisis. Financial statements and comments in general and internal transactions were extracted from TS-2000 of the Korea Listed Company Association, and data related to stock price were extracted from KISVALUE-III of National Information and Credit Evaluation Information Service Co., Ltd. STATA 12.0 was used as the statistical package for panel analysis.
Results
In the pharmaceutical firms, the influence of the R&D intensity with regard to Tobin's q was found to be positive. However, only the R&D expenditure intensities of previous years 2 and 5 (t–2 and t–5, respectively) were statistically significant (p < 0.1), whereas those of previous years 1, 3, and 4 years (t–1, t–3, and t–4, respectively) were not statistically significant.
Conclusion
R&D investment not only affects the enterprise value but is also evaluated as an investment activity that raises the long-term enterprise value. The research findings will serve as valuable data to understand the enterprise value of the Korea pharmaceutical industry and to strengthen reform measures. Not only should new drug development be made, but also investment and support should be provided according to the specific factors suitable to improve the competitiveness of each company, such as generic, incrementally modified drugs, and biosimilar products.

Citations

Citations to this article as recorded by

R&D investment and corporate total factor productivity under the heterogeneous environmental regulations: evidence from Chinese micro firms
X. Ding, Y. Zhang, Y. Fu, Z. Xu
International Journal of Environmental Science and.2024;[Epub] CrossRef
A new perspective for European SMEs’ innovative support analysis: Does non-financial support matter?
Solomon Gyamfi, Wolfgang Gerstlberger, Viktor Prokop, Jan Stejskal
Heliyon.2024; 10(1): e23796. CrossRef
R&D activity and firm performance: mapping the field
Kseniia Boiko
Management Review Quarterly.2022; 72(4): 1051. CrossRef
Pharmaceutical industry in export marketing: a closer look at competitiveness
Mehdi Mohammadzadeh, Nima Bakhtiari, Reza Safarey, Tayebeh Ghari
International Journal of Pharmaceutical and Health.2021; 13(3): 331. CrossRef
The effect of intangible assets on sustainable growth and firm value – Evidence on intellectual capital investment in companies listed on Bucharest Stock Exchange
Catalin Ionita, Elena Dinu
Kybernetes.2021; 50(10): 2823. CrossRef
AR-GE GİDERLERİ İLE KÂRLILIK VE BÜYÜME ARASINDA NEDENSELLİK İLİŞKİSİ: BIST ÜZERİNE BİR İNCELEME
Mehmet DİKİCİ, Kadir GÜRDAL
Muhasebe ve Vergi Uygulamaları Dergisi.2021; 14(3): 1193. CrossRef
R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry
Chih-Yi Su, Yao-Ning Guo, Kuang-Cheng Chai, Wei-Wei Kong
Frontiers in Public Health.2021;[Epub] CrossRef
R&D SPENDING AND FINANCIAL PERFORMANCE: AN INVESTIGATION IN AN EMERGING MARKET
Nasıf ÖZKAN
International Journal of Management Economics and .2021;[Epub] CrossRef
The persistence of current market valuation of future capital investment
Nancy Beneda
Journal of Corporate Accounting & Finance.2020; 31(3): 163. CrossRef
Sustainability assessment of universities as small-scale urban systems: A comparative analysis using Fisher Information and Data Envelopment Analysis
Ning Ai, Marc Kjerland, Cynthia Klein-Banai, Thomas L. Theis
Journal of Cleaner Production.2019; 212: 1357. CrossRef
Analysing future change in the EU's energy innovation system
Yeong Jae Kim, Charlie Wilson
Energy Strategy Reviews.2019; 24: 279. CrossRef
A review of three years' experience of the first pharmacometrics company in Korea
So Jin Lee, Sangil Jeon
Translational and Clinical Pharmacology.2019; 27(4): 149. CrossRef
The impact of inter-industry R&D technology spillover on carbon emission in China
Jianling Jiao, Yufei Yang, Yu Bai
Natural Hazards.2018; 91(3): 913. CrossRef
Characteristics of Corporate R&D Investment in Emerging Markets: Evidence from Manufacturing Industry in China and South Korea
Jian Xu, Jae-Woo Sim
Sustainability.2018; 10(9): 3002. CrossRef
R&D Investments, EPO Patent Applications and the Economic Heterogeneity within the EU
Zuzana Potužáková, Jan Öhm
Review of Economic Perspectives.2018; 18(2): 177. CrossRef

First
Prev
Page of 1
Next
Last

Search